Edward A. Sausville

Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities

Vincent Y. Ng, Mario N Sahlani, Anthony Kohler Chiu, Michael Edward Kallen et autres

Background The current management of large, high-grade soft tissue sarcoma (STS) of the trunk and extremities includes radiation and surgical resection. The initial use of chemotherapy and targeted therapy are controversial and although most patients present with localized disease, many eventually develop …

us (code pays fourni par la source)

Editor's Note: Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator

Gurmeet Kaur, Dorina Belotti, Angelika M. Burger, Kirsten Fisher-Nielson et autres

us (code pays fourni par la source)

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

Oluwadunni E. Emiloju, Jun Yin, Emily J. Koubek, Joel M. Reid et autres

us (code pays fourni par la source)

Antimitotics

Edward A. Sausville, Ashkan Emadi

Alkylating Agents and Drugs Perturbing DNA Structure

Ashkan Emadi, Edward A. Sausville

Drug Development in Oncology

Edward A. Sausville, Ashkan Emadi

The notion that cancer might be usefully treated by drugs is relatively new, as surgery was the mainstay of therapeutic approaches to cancer, and even when radiation was found to cause useful effects on tumors, its use was as an alternate local …

Cancer Pharmacology

Ashkan Emadi, Judith E. Karp, Edward A. Sausville, Molly Graveno et autres

Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer

Ben Atkinson, Abdolrahim Abassi, Mohammad Mohseni Sajadi, Zahra Rikhtegaran Tehrani et autres

Non-small cell lung cancer (NSCLC) is the most fatal non-AIDS defining cancer in people living with HIV (PWH) on antiretroviral therapy (ART). Treatment of malignancies in PWH requires concomitant cancer therapy and ART, which can lead to potential drug–drug interactions (DDIs) and …

us (code pays fourni par la source)

Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia Mucci LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun et autres

Supplementary Figure S1. Study schema.

Supplementary Figure 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia Mucci LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun et autres

Supplementary Figure S4. Assessment of pNBS1 in the exploratory multiplex immunofluorescence assay.

Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia Mucci LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun et autres

Supplementary Table 1 Pharmacokinetic parametersa of veliparib and its main metabolite (A- 925088) when veliparib was given orally alone on cycle 2 day -1 or in combination with irinotecan on cycle 2 day 8

Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia Mucci LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun et autres

Supplementary Figure S3. pNBS1 staining post-combination treatment is limited to tumor cells.